Teva. Another FDA approval
צילום: סבאסטיאן שיינר
Teva fungus drug gets FDA nod
Israeli-based drug maker says it was granted final approval to market a generic version of Novartis AG's fungus treatment Lamisil
Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration granted the generic drug developer final approval to market a generic version of Novartis AG's fungus treatment Lamisil.
The FDA approved the Israeli-based company's application for 250-milligram terbinafine hydrochloride tablets.
The patent for Lamisil, which kills fungus under fingernails and toenails, expired June 30.
In 2006, Novartis generated $574 million in US sales from Lamisil.
Shipment of Teva's generic will begin immediately.
On Monday, more than a dozen generic drug makers received FDA approval to market low-cost versions of Lamisil.
Questions or comments about this story should be directed to AP Financial News at 212-621-7190.
